Oruka Therapeutics, Inc. ORKA | NASDAQ
Company Overview:
10 Year ORKA Performance Metrics:
ORKA Dividend Charts
Build Custom Charts
ORKA Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
ORKA Dividends Info:
ORKA Dividend History: Dates, Payments & Yield list
Below is a schedule of all ORKA dividend payments, ex-dates, share price on the day of the payment as well as the annualized yield & forward yield
| Ex-Date | Payment Date | Amount | Yield | Forward Yield | Price on Ex-Date |
|---|---|---|---|---|---|
| 08/29/2024 | 09/02/2024 | $19.356 | 258.08% | 0% | $0.00 |
Projected Future Returns & Dividends for ORKA
Based on past 10-year performance, here are ORKA growth metrics:
Share price CAGR of -15.01%
Dividend CAGR of +0%
Using ORKA CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| ORKA (DRIP) | ORKA - No DRIP | |
|---|---|---|
| Current Price | $105.35 | $105.35 |
| Start Shares | 94.92 | 94.92 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 80,812.37 | 94.92 |
| Dividends Payment | $3.81 | $3.81 |
| Annual Dividends | $1,230,503 | $1,445 |
| Yield on cost | 12,305.03% | 14.45% |
| Share Price | $20.72 | $20.72 |
| Total Dividends | $2,397,759 | $39,336 |
| Final Value | $1,674,332 | $41,302 |
NOTE: Above numbers are our estimate based on ORKA's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Company Info
Oruka Therapeutics, Inc. (ORKA) had its IPO on 1997-08-08, and is traded on NASDAQ stock exchange.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
ORKA website: http://www.orukatx.com
DCF Model — ORKA
FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.
EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.
| Year | FCF | Implied price |
|---|
